|
|
Article: Anthera Raises $36M To Fund Phase II Inflammation Studies.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
A week after in-licensing two clinical stage anti-inflammatory compounds from Eli Lilly and Co., specialty pharma firm Anthera Pharmaceuticals Inc. closed its first institutional financing round of $36 million.
The company previously raised about $1.5 million in seed funding in 2005, which was used to bring in its first pipeline products. Earlier this month, Anthera completed that licensing agreement, gaining worldwide rights, except for Japan, to a secretory phospholipase program from Indianapolis-based Lilly and Osaka, Japan-based Shionogi & Co. Ltd. Terms were not disclosed.
"Our business model is to develop compounds that have ...